Ribon instrument was sentenced to tort compensation 36 million and three years of the end

More than three years, Mai Rui Medical International Limited (NYSE:MR, hereinafter referred to as "Mary") v. Ribon instrument (300206.SZ) Tort case is finally nearing the end. July 8, the economic reporter from close to the people in the 21st century learned that Mary received from the senior People's Court in Guangdong Province (hereinafter referred to as "Guangdong Province High Court") and the Shenzhen Intermediate Court (hereinafter referred to as "Shenzhen") issued three civil judgments, the State instrument (300206.SZ) were defeated, was sentenced to infringement of the establishment, Need to compensate for 1 million yuan, 20 million yuan, 15 million yuan. Reporter learned that the former for the Guangdong Provincial High Court final results, the latter two for the Shenzhen Institute of First Instance results. As early as April 2011, the state instruments on the eve of the listing, Mary's prosecution of the state instruments violated its 23 patents and involved in 1 commercial secrets cases, the amount of litigation gradually rose to 106.997 million yuan, after the case, Mary withdrew the 1 patent cases. Li Xiaofi, manager of the Intellectual Property Department, told the 21st century economic reporter that the three civil judgments actually involved 9 cases (including 8 patent cases and one trade secret case), and that the remaining 11 patents were withdrawn in addition to 3 pending patents. "The 3 patent cases now awaiting a verdict, the victory is more clear, the amount of compensation may be about 2 million yuan per patent case." "The total amount of compensation is expected," Li Xiaofi said. "It also means that the infringement case that has plagued the Ribon instrument for more than three years will end." It is noteworthy that Li Xiaofi to reporters, "these cases involved in the infringement of the time from the prosecution for two years forward, and in the prosecution after the infringement, we can still apply for a compensation case, but specifically how to determine the company is still being considered." "As of press, the reporter did not see Ribon instruments have related proceedings progress notice." The reporter then contacted the state instrument related personnel to verify, the company said: "This is a major issue of the company, according to information disclosure requirements, if the company received a verdict will be issued within two days interim notice." "The reporter asked whether the company has received the verdict at present, the other side said" it is not clear. " "The result of the tort dispute case, has certain influence to the Ribon instrument in the short term, as long as the influence depends on how to deal with the Ribon management." "Analysis of the 21st century Economic report by the medical device industry analyst at a brokerage in South China. As of July 8, the state instruments fell slightly 0.51%, closing the 21.25 yuan/share. Ribon Mayry "Hatred record" three are signed at the end of June, will be the last three years of the state instrument of the infringement dispute and back to the public eye. The aforementioned close to the people told reporters, "a portable ultrasound" patent infringement of the second instance of the civil judgments are: to maintain the first instance of the original judgment; State Company infringement, infringement products covered by the state's portable Black-and-white products Dus6vet, the total amount of compensation for 1 million yuan, The related litigation fee and appraisal fee shall be borne by Ribon. "This is the first case in the Ribon series of lawsuitsFinal Judgment. "In addition, the person said, Mary received the Shenzhen Intermediate People's Court (hereinafter referred to as" Shenzhen ") issued by the first-instance civil judgments (including trade secret cases and noninvasive blood pressure patent infringement cases) the main contents of the verdict: The state company infringement established, infringing products covering all its multi-parameter monitor products, The total amount of compensation is RMB 35 million (trade secret case 20 million and noninvasive blood pressure patent infringement case 15 million), the related litigation fee and appraisal cost are borne by the State company. Tort case to win, Ribon instrument lost a paragraph. However, once the "Same gate", an important partner, why in three years ago suddenly in court? "Mary in the domestic medical equipment field is the leading boss, this is beyond doubt, and the state instrument is not actually a rising star, it and Mary is actually the same origin." "For the market said" Mary is the industry leader, the state instrument is an up-and-comer, "said the medical device industry analyst. According to the public information, the founder of Mary Xuhang and the state instrument founder Zhang Hao, Shesi, Lu Liang early in the Shenzhen medical Equipment Company service, there are media called "the same gate." And the two companies in Shenzhen are indeed important partners. Ribon Instrument Prospectus shows that the Ribon instrument in 2008, 2009, the largest domestic customers, of which in the 2008 export customers, Mary is the only listed in the domestic company. 2010 is still the second largest Ribon instrument sales customers. Beginning in 2011, according to the 21st Century Economic Report reporter inquires, the state instruments of the annual report does not have a specific list of the top five customer names. In the capital markets, Mary first step, in October 2006, the United States listed on the NYSE, the state instruments in April 2011 on the A-share gem listed. After the Ribon instrument completed the IPO inquiry, the dispute between the two sides about tort began to surface. Mary to sue for infringement of the State apparatus, involving 23 patents and involved in 1 commercial secret cases, Mary asked Ribon instruments to destroy the relevant infringing products, stop infringement, the amount of litigation from the original 25 million yuan to the later 106.997 million yuan. "They used to represent our products, we would buy their products, they were exchanging goods, but then they started copying some of our products." Li Xiaofi said. The Ribon instrument also reacted accordingly, in the April 21, 2012 announcement, the company said, the company's related monitoring, ultrasound imaging products, independent research and development, did not infringe on the company's patents, even if the company involved in the infringement case, the issuer involved in the case claims infringement of the product nearly three years of sales revenue less than 20%, Gross margin ratio is less, does not affect the company's continued ability to operate. May 2012, because of Mary to Ribon instrument customers to send legal documents such as lawyer letter, the state instrument to counterattack, to the Shenzhen Institute filed a lawsuit, ask for 50 million yuan compensation. The case ended in a lawsuit against the state instrument. In "Trade secret case", Mai Rui said, the company's original staff Wang Yi and other people in MaiRUI Research and Development department work, after the Ribon instrument work involved in the development of technical secrets involved in the work. Ribon instrument argues that "the flow of people is a normal phenomenon, and that the employees know that the business secrets have no factual basis." In the end, the case ended in the first instance with a lawsuit against the state instrument. Judging from the closing date of the verdict June 25, 2014, including commercial secret cases and non-invasive blood pressure patent infringement cases, the state instruments can still be on the date of the judgement on the 15th to the Shenzhen Institute of Litigation filed, appeal to the Guangdong Province High Court. Back and forth, Mary, Ribon instrument The two companies also involved in the patent and the state Intellectual Property Office Patent Review Board Many representations, disputes continue, and even involved in litigation. "In fact, none of the patents are completely void, and some cases involve partially ineffective patents," he said. "Li Xiaofi said. The Ribon of the road to the future many market participants said that behind the trade secrets and patent infringement cases, because of the state instruments and the race for the rival, so led to the three-year dispute. "Mary tells the state instrument, that he is more important to his opponents, in fact, not only in the field of medical devices, domestic issues such as tort in all areas are in fact universal, such problems in the short term difficult to change." "The former Securities analyst said. According to the 21st Century Economic Report reporter, in the infringement case, was identified as infringing products for ultrasound imaging four products and guardianship of eight products. In the Ribon Instrument 2010 Annual Sales revenue of 317.7699 million yuan, suspected infringement of the company custody, ultrasound two series of products sales revenue accounted for its main business sales income ratio of 46.16%. This is not the same as the state of the instruments identified less than 20% of the discrepancy. "This ratio is based on the prospectus data, the guardianship contains some other products, may be the other party to adjust the product structure, the difference between the statistical caliber leads to differences." "Li Xiaofi said. He said that the 3 patent infringement cases currently before the Court were the same as the patents in the aforementioned "one portable ultrasound" patent infringement case. "The 3 patent cases that we are trying to claim are 3 million yuan, 5 million yuan and 7 million yuan respectively, but the result may be about 2 million yuan per patent case." Li Xiaofi to reporters. This means that if there is no directional change in the case, the state apparatus may have to pay a cost of $42 million to compensate for it. From the current financial situation of the RIBON instrument, it is not a big problem to pay the compensation amount of $42 million. At the end of the first quarter of 2014, the state Instrument Currency Fund was 905 million yuan. Ribon Instrument Actual Control person Zhang Hao, Shesi, Zu have written promise, will jointly bear the company due to litigation arising from tort compensation, case costs and production, business losses. But, judging from its own performance, some private-equity insiders point out that "the performance of State instruments has not yet been followed by the current high market value." "Earnings showed that the state instruments 2011, 2012, 2013 net profit of 59.2723 million yuan, 55195,700 yuan, 32.7029 million yuan, fell 10.22%, 6.74%, 37.13% respectively. "The infringement case has gone through a long time, the result of the case to the Ribon instrument influence is to pay some compensation amount of financial expenses, but in the long term, I think the state instrument still has some aspect." Wang Zhizhong, chairman of Shenzhen Ming Yuan Investment Advisory Co., Ltd., who has investigated Ribon instruments, analyzed the 21st century economic reporter. In the view of the former brokerage analysts, the continued capacity of the State instrument is not impaired by the case. "The state instrument has been in the proportion of input to adjust to weaken the color of the extra investment, to increase its view more promising areas." ”